• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300026.SZ
Share

Tianjin Chase Sun Pharmaceutical Co.,Ltd Stocks

CN¥ 3.2Last Updated 28.05.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.43B

CN¥ 3.2
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Low dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet based therapy. It is also involved in the research and development of various drugs in the areas of sepsis, pulmonary hypertension, leukemia, cardiovascular and cerebrovascular diseases, arthritis, ischemic stroke, HCV, vascular disease, psychosis, and chemotherapy, as well as anesthesia drugs and immunomodulators. The company was founded in 1996 and is based in Tianjin, China.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 300026.SZ is 4.3 and suggests 34% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.05.2026 03:55

Investors have bought up drone makers' shares: White House discusses support for the industry

29.05.2026 02:41

Iranian media reported warning strikes on ships attempting to pass Hormuz

29.05.2026 01:39

U.S. stock market hits four records: investors await U.S.-Iran agreement

29.05.2026 00:43

Anthropic has surpassed OpenAI to become the most expensive AI startup. The valuation is close to $1 trillion

29.05.2026 00:08

Anthropic has introduced a new AI model. It can doubt the accuracy of its answers

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026